Edition:
India

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

53.63USD
11:15pm IST
Change (% chg)

$0.24 (+0.45%)
Prev Close
$53.39
Open
$53.53
Day's High
$54.11
Day's Low
$53.48
Volume
4,666
Avg. Vol
35,928
52-wk High
$60.28
52-wk Low
$41.64

Select another date:

Thu, Oct 26 2017

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

BRIEF-Anika announces forthcoming appointment of Thomas Finnerty as chief human resources officer

* Anika announces the forthcoming appointment of Thomas M. Finnerty as chief human resources officer Source text for Eikon: Further company coverage:

BRIEF-Anika Therapeutics announces regulatory approval for Monovisc® in Australia

* Anika announces regulatory approval for Monovisc® in Australia for the treatment of pain associated with osteoarthritis of all synovial joints

BRIEF-Kayne Anderson Rudnick Investment Management Llc reports 11.49 pct passive stake in Anika Therapeutics Inc as of August 08, 2017 - SEC filing

* Kayne anderson rudnick investment management llc reports 11.49 percent passive stake in anika therapeutics inc as of august 08, 2017 - sec filing Source text - (http://bit.ly/2fqZxZ8) Further company coverage:

BRIEF-Anika announces appointment of Joseph Darling as president

* Anika therapeutics - co's ceo dr. Charles h. Sherwood who served as president, plans to transition role to darling, while continuing tenure as ceo Source text for Eikon: Further company coverage:

BRIEF-Anika announces regulatory approval for Monovisc in India

* Anika announces regulatory approval for Monovisc in India for the treatment of pain associated with osteoarthritis of all synovial joints Source text for Eikon: Further company coverage:

BRIEF-Anika announces $5 mln milestone payment from U.S. commercial sales of Monovisc

* Anika announces $5 million milestone payment from U.S. Commercial sales of Monovisc

BRIEF-Anika Therapeutics expects to complete supplemental phase III trial of CINGAL in 2018

* Anika announces first patient enrolled in supplemental phase III trial of CINGAL for the treatment of knee pain associated with osteoarthritis

Select another date: